Bioburden Testing Market 2015 - Global Forecasts to 2019
DUBLIN, June 02, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing) has announced the addition of the "Bioburden Testing Market by Product , Test, Application & End User - Forecast to 2019" report to their offering.
The bioburden testing market is expected to reach $565.6 Million by 2019 from $354.4 Million in 2014, growing at a CAGR of 9.8% from 2014 to 2019
On the basis of products, the microbial limit testing market is segmented into consumables and instruments. The consumables market is further segmented into culture media and reagents & kits and other consumables. The instruments market is further segmented into PCR, microscopes, automated microbial identification systems, and other instruments.
On the basis of test types, the global bioburden market is segmented into aerobic count, anaerobic count, fungi/mold count, and spores count. On the basis of applications, the market is segmented into raw material testing, medical devices testing, in-process testing, sterilization validation testing, and equipment cleaning validation.
Based on end users, the market is segmented into pharmaceutical and biotechnology companies, medical devices manufacturers, contract manufacturing organizations (CMOs), manufacturers of food & beverage and agricultural products, and microbial testing laboratories.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Industry Insights
7 Bioburden Testing Market, By Product
8 Bioburden Testing Market, By Test Type
9 Bioburden Testing Market, By Application
10 Bioburden Testing Market, By End User
11 Geographic Analysis
12 Competitive Landscape
13 Company Profiles
- ATS Labs, Inc.
- Becton, Dickinson, and Company
- Charles River Laboratories International, Inc.
- Merck & Co., Inc.
- Nelson Laboratories, Inc.
- North American Science Associates, Inc. (NAMSA)
- Pacific Biolabs
- SGS S.A.
- Sigma-Aldrich Corporation
- WUXI Pharmatech (Cayman), Inc.
For more information visit http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article